<DOC>
	<DOC>NCT01406574</DOC>
	<brief_summary>The purpose of this study is: Phase1: To evaluate the safety and determine the recommended dose (RD) Phase2: To evaluate the efficacy</brief_summary>
	<brief_title>Phase I/II Study of OPB-31121 in Patients With Progressive Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<criteria>Patients with histopathologically or clinically confirmed diagnosis of hepatocellular carcinoma Patients with ChildPugh classification A or B Patients unresponsive to standard therapy or for whom standard therapy is intolerable, or for whom there is no appropriate therapy Patients who are able to take oral medication Patients age 20 to 79 years (inclusive) at time of informed consent Patients with an ECOG performance status score of 02 Patients have the eligible organ function. Patients with a primary malignant tumor Patients with a history of liver transplant Patients with brain metastases Patients with a complication of uncontrolled Patients with a psychiatric disorder that might cause difficulty in obtaining informed consent or in conducting the trial</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Hepatocellular carcinoma</keyword>
</DOC>